Vaccine effectiveness against COVID-19 hospitalization in adults in France: A test negative case control study

被引：6

作者：

Ngyen, Liem Binh Luong ^{[1
]}

Bauer, Rebecca ^{[2
]}

Lesieur, Zineb ^{[3
]}

Galtier, Florence ^{[4
]}

Duval, Xavier ^{[5
]}

Vanhems, Philippe ^{[6
]}

Laine, Fabrice ^{[7
]}

Tattevin, Pierre ^{[8
,9
]}

Durier, Christine ^{[2
]}

Launay, Odile ^{[1
,3
]}

机构：

[1] Hop Cochin, AP HP, INSERM, CIC 1417, Paris, France

[2] INSERM, US19, Villejuif, France

[3] F CRIN I REIVAC, INSERM, Paris, France

[4] CHU Montpellier, St Eloi Hosp, INSERM, CIC 1411, Montpellier, France

[5] Hop Bichat Claude Bernard, AP HP, INSERM, CIC 1425, Paris, France

[6] Hosp Civils Lyon, Serv Hyg Epidemiol Infectiovigilance & Prevent, Lyon, France

[7] CHU Rennes, Inserm CIC 1414, Rennes, France

[8] CHU Rennes, Hop Pontchaillou, Serv Malad Infect, Rennes, France

[9] CHU Rennes, Hop Pontchaillou, Serv Reanimat Med, Rennes, France

来源：

INFECTIOUS DISEASES NOW | 2022年 / 52卷 / 01期

关键词：

Alpha variant; COVID-19; France; Vaccine; Vaccine effectiveness;

D O I：

10.1016/j.idnow.2021.12.002

中图分类号：

R51 [传染病];

学科分类号：

100401 ;

摘要：

Background: Measuring vaccine effectiveness (VE) using real-life data is critical to confirm the effectiveness of licensed vaccine, which could strengthen vaccination adherence. Methods: We measured VE against adult COVID-19 hospitalization in five hospitals in France using a test negative design. We compared the odds of vaccinated patients hospitalized with COVID-19 with the odds of vaccinated patients hospitalized for the same symptoms with a negative test. Results: A total of 853 patients (463 cases and 390 controls) were included, with a total of 170 patients vaccinated (104 with one dose, 65 with two doses, and one with three doses). There were four cases of breakthrough infections, all in immunocompromised patients. The VE was 84.0% (CI0.95 = [72.6; 90.6]) for one dose and 96.2% (CI0.95 = [86.8; 98.9]) for two doses. Conclusion: Our results confirm the high VE of COVID-19 vaccine in France to prevent hospitalizations due to the alpha variant.

引用

页码：40 / 43

页数：4

共 50 条

[41] BBIBP-CorV vaccine effectiveness against COVID-19 in patients aged 60 years and older during the Delta-dominant period in the Federation of Bosnia and Herzegovina, a test-negative case-control study
Musa, Sanjin
Merdrignac, Lore
Skocibusic, Sinisa
Nedic, Rozalija
Cilovic-Lagarija, Seila
Kissling, Esther
VACCINE, 2024, 42 (15) : 3467 - 3473
[42] Influenza vaccine effectiveness against influenza-related hospitalization during a season with mixed outbreaks of four influenza viruses: a test-negative case-control study in adults in Canada
Melissa K. Andrew
Vivek Shinde
Todd Hatchette
Ardith Ambrose
Guy Boivin
William Bowie
Ayman Chit
Gael Dos Santos
May ElSherif
Karen Green
François Haguinet
Scott A. Halperin
Barbara Ibarguchi
Jennie Johnstone
Kevin Katz
Joanne M. Langley
Jason LeBlanc
Mark Loeb
Donna MacKinnon-Cameron
Anne McCarthy
Janet McElhaney
Allison McGeer
Michaela K. Nichols
Jeff Powis
David Richardson
Makeda Semret
Grant Stiver
Sylvie Trottier
Louis Valiquette
Duncan Webster
Lingyun Ye
Shelly A. McNeil
BMC Infectious Diseases, 17
[43] Effectiveness of the Original COVID-19 Vaccine against COVID-19 Exacerbations during the Omicron Wave: A Population-based Study in Okayama, Japan
Matsumoto, Naomi
Mitsuhashi, Toshiharu
Matsuo, Rumi
Kadowaki, Tomoka
Takao, Soshi
Yorifuji, Takashi
JMA JOURNAL, 2023, 6 (04): : 463 - 469
[44] Trajectories of Hospitalization in COVID-19 Patients: An Observational Study in France
Boelle, Pierre-Yves
Delory, Tristan
Maynadier, Xavier
Janssen, Cecile
Piarroux, Renaud
Pichenot, Marie
Lemaire, Xavier
Baclet, Nicolas
Weyrich, Pierre
Melliez, Hugues
Meybeck, Agnes
Lanoix, Jean-Philippe
Robineau, Olivier
JOURNAL OF CLINICAL MEDICINE, 2020, 9 (10) : 1 - 12
[45] Real-World Effectiveness of COVID-19 Vaccines against Severe Outcomes during the Period of Omicron Predominance in Thailand: A Test-Negative Nationwide Case-Control Study
Nittayasoot, Natthaprang
Suphanchaimat, Rapeepong
Thammawijaya, Panithee
Jiraphongsa, Chuleeporn
Siraprapasiri, Taweesap
Ploddi, Kritchavat
Pittayawonganon, Chakkarat
Mahasirimongkol, Surakameth
Tharmaphornpilas, Piyanit
VACCINES, 2022, 10 (12)
[46] Interim estimates in null models of COVID-19 vaccine effectiveness
Lisewski, Andreas Martin
INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2021, 106 : 169 - 170
[47] Influenza Vaccine Effectiveness against Hospitalization, Season 2021/22: A Test-Negative Design Study in Barcelona
Fornaguera, Mar
Pares-Badell, Oleguer
Carbones-Fargas, Ingrid
Andres, Cristina
Rodrigo-Pendas, Jose Angel
Borras-Bermejo, Blanca
Armadans-Gil, Lluis
Tejada, Gabriela
Guananga, David
Vivet-Escale, Marti
Penalver-Pinol, Arnau
Torrecilla-Martinez, Irene
del Oso, Arnau
Martinez-Gomez, Xavier
Anton, Andres
Otero-Romero, Susana
VACCINES, 2023, 11 (09)
[48] Influenza vaccine effectiveness against influenza-related hospitalization during a season with mixed outbreaks of four influenza viruses: a test-negative case-control study in adults in Canada
Andrew, Melissa K.
Shinde, Vivek
Hatchette, Todd
Ambrose, Ardith
Boivin, Guy
Bowie, William
Chit, Ayman
Dos Santos, Gael
ElSherif, May
Green, Karen
Haguinet, Francois
Halperin, Scott A.
Ibarguchi, Barbara
Johnstone, Jennie
Katz, Kevin
Langley, Joanne M.
LeBlanc, Jason
Loeb, Mark
MacKinnon-Cameron, Donna
McCarthy, Anne
McElhaney, Janet
McGeer, Allison
Nichols, Michaela K.
Powis, Jeff
Richardson, David
Semret, Makeda
Stiver, Grant
Trottier, Sylvie
Valiquette, Louis
Webster, Duncan
Ye, Lingyun
McNeil, Shelly A.
BMC INFECTIOUS DISEASES, 2017, 17
[49] Waning COVID-19 vaccine effectiveness in Japan
Kurita, Junko
Sugawara, Tamie
Ohkusa, Yasushi
DRUG DISCOVERIES AND THERAPEUTICS, 2022, 16 (01) : 30 - 36
[50] COVID-19 vaccine effectiveness monitoring in Australia
Liu, Bette
MICROBIOLOGY AUSTRALIA, 2024, 45 (04) : 193 - 195

← 1 2 3 4 5 →